Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modif
February 09 2010 - 8:30AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) announced today it has been advised by the Data Safety
Monitoring Board ("DSMB") that its third and final regularly
scheduled safety analysis has been completed and the DSMB has
recommended for the Phase IIb acute ischemic stroke trial to
continue as per protocol.
Dr. Alan Moore, President and CEO, commented as follows:
"Since the initiation of the modified REGENESIS Phase IIb acute
ischemic stroke study, 96 patients have been enrolled in the study.
We continue to anticipate that patient enrollment for the Phase IIb
stroke trial will be complete by the end of Q1 2010 and for
top-line data to be available after the 90-day patient assessment
review period is complete, approximately by the end of Q2
2010."
About the Data Safety Monitoring Board ("DSMB"): The DSMB is a
group of independent clinical experts that review the ongoing
conduct of a clinical trial to ensure continuing patient safety.
The mandate of SCT's DSMB is to provide objective, independent
monitoring of patient safety during the Phase IIb acute ischemic
stroke trial. This review was the third of three formal meetings
scheduled to occur over the duration of the Phase IIb stroke
trial.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Chloe Douglas-Crampton Investor Relations (403)
245-5495 ext. 221 crampton@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024